These HER2 receptors receive signals that stimulate the growth of breast cancer cells. However, FISH is considered more accurate. Research has shown that some HER2 test results may be wrong.
BCIRG randomized patients with HER2 -not-amplified breast cancers to sequential arm 1 or concurrent arm 2 anthracycline, cyclophosphamide, and docetaxel chemotherapy. AC-T indicates anthracycline, cyclophosphamide, and docetaxel; ACTH, anthracycline, cyclophosphamide, docetaxel, and trastuzumab; TAC, taxotere, docetaxel, and cyclophosphamide; TCH, docetaxel, carboplatin, and trastuzumab. The location of chromosome 17 centromere is highlighted in red.
Genes contain the recipes for the various proteins a cell needs to stay healthy and function normally. Some genes and the proteins they make can influence how a breast cancer behaves and how it might respond to a specific treatment. Cancer cells from a tissue sample can be tested to see which genes are normal and abnormal.
HER2 proteins are present on the surface of some breast cancer cells. Normally, HER2 proteins regulate and control the growth of breast cells. But when the HER2 gene is mutated, which is the case in about 1 in every 5 cases of breast cancer, it makes too many HER2 proteins. This results in breast cells growing and dividing out of control.
This somatically acquired genetic alteration is associated with shorter disease-free and overall survival of patients in the absence of HER2-targeted therapy. Because HER2 -targeted therapies have significantly improved outcomes for patients whose cancers have this alteration, accurate assessment of the alteration with companion diagnostics has become critically important. At the time when these guidelines were published, there were no studies using this interpretative strategy and, therefore, no available data related to prevalence rates of each FISH group, correlation of each FISH group with HER2 protein expression, or correlation of each group with clinical outcomes, either with or without HER2 -targeted therapies.
Impact factor 3. International Journal of Biological Sciences. International Journal of Medical Sciences.
Working with our dedicated and highly trained Surgical Pathology Team at UR Medicine Labs means that you will receive quicker turnaround for results and personal attention to your cases. You can be assured that you are getting the best in clinical laboratory testing such as:. Proper results determine the course of therapy for Breast and Gastric Cancer patients.
The gold standard of HER2 status assessment in breast cancer is still debated. Immunohistochemistry IHC and in-situ technology as fluorescent-labeled methodology FISH can be influenced by pre-analytical factors, assay-conditions and interpretation of test results. We retrospectively conducted this quality control study and analyzed HER2 test results in breast cancer within the routine diagnostic service in a single institution over a period of 12 years. Data of consecutive HER2-FISH-assays in a period of 12 years — on breast cancer biopsies and excision specimens were retrospectively analyzed.
Please take this quick survey to tell us about what happens after you publish a paper. Breast Cancer Research and Treatment. While HER2 testing is well established in directing appropriate treatment for breast cancer, a small percentage of cases show equivocal results by immunohistochemistry IHC and fluorescence in situ hybridization FISH.